FDA approves Abeona's $3.1m cell therapy for rare skin disease
Abeona Therapeutics has secured US Food and Drug Administration (FDA) approval for Zevaskyn (prademagene zamikeracel), a gene-corrected cell therapy designed to treat recessive dystrophic epidermolysis bullosa (RDEB).
The approval follows years of clinical development and regulatory setbacks, and positions Abeona as the second company to bring a therapy for this condition to the US market.
Also known as pz-cel, Zevaskyn is indicated for both paediatric and adult patients with RDEB. The therapy is administered as credit card-sized sheets of skin made from the patient's own keratinocytes, which are harvested, genetically modified to express the functional COL7A1 gene, and surgically applied to chronic wounds. The COL7A1 gene encodes a type of collagen essential for anchoring skin layers – something patients with RDEB lack due to genetic mutations.
The FDA had previously rejected an application from Abeona last year, citing outstanding manufacturing and quality control (QC) concerns. Following a complete response (CR) letter and further chemistry, manufacturing and controls (CMC) submissions, the agency granted approval based on results from a pivotal Phase III study (NCT04227106).
Despite a partial clinical hold in 2019, the study met both co-primary endpoints of wound healing and pain reduction, with no serious treatment-related adverse events (AEs) reported. The company also provided confirmatory evidence from a Phase I/IIa trial (NCT01263379), which supported the durability of healing after a single application.
Zevaskyn is priced at $3.1m, placing it among the most expensive therapies in the US but in line with other rare disease gene and cell therapies. Abeona expects to make the product available commercially in Q3 2025. The company raised $35m in late 2022 after announcing the Phase III data, followed by a $25m financing round in July 2024 to support manufacturing and launch readiness.
Krystal Biotech's Vyjuvek (beremagene geperpavec), a topical gene therapy gel for DEB, was approved in 2023 and generated $290.5m in revenue in 2024. Unlike Zevaskyn, which is applied once through surgery, Vyjuvek is dosed weekly and costs around $631,000 per patient per year. Vyjuvek also delivers a functional COL7A1 gene, though via a re-dosable, non-integrating viral vector.
In the 29 April announcement, Abeona's CEO Vish Seshadri, said: 'We have heard from the RDEB community that there is a persistent unmet need to reliably address RDEB wounds, especially those that are chronic and prone to infection. Through a single surgical application, Zevaskyn can now offer people with RDEB the opportunity for wound healing and pain reduction in even the most severe wounds, as evidenced by the results from our pivotal Phase III study.'
In connection with the approval, Abeona received a rare paediatric disease priority review voucher (PRV), which the company said it plans to monetise. The PRV programme, which grants expedited FDA review for a future drug application, is set to expire soon unless renewed by Congress. Rare disease advocates have warned that the programme's lapse, combined with existing FDA resource constraints, could deter future investment in paediatric rare disease research and development.
"FDA approves Abeona's $3.1m cell therapy for rare skin disease" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand.
The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
18 minutes ago
- Yahoo
The FDA Just Updated a Recall on This Popular Summer Produce To Its Highest Classification—Here's What to Know
The FDA Just Updated a Recall on This Popular Summer Produce To Its Highest Classification—Here's What to Know originally appeared on Parade. Not to be an alarmist, but if you aren't paying attention to our food system yet, you might want to start. In recent weeks, we have seen a slew of recalls affecting everything from cucumbers, sausages, frozen meals, and canned goods, causing us to wonder if any of the food in our home is safe. Sure, there's some level of normal when it comes to said recalls—some are simply due to missed ingredients on labels or an incorrect sell-by date—but the more nefarious cases of salmonella, listeria, and E. coli are not something we should be taking lightly. 😋😋SIGN UP to get delicious recipes, handy kitchen hacks & more in our daily Pop Kitchen newsletter🍳🍔 In some ways, this current era of unknowns within our food supply chain isn't new or asymptomatic, but it's worth it to note that it isn't getting any better. Regulatory agencies are being cut left and right, and systems meant to protect us have become virtually non-existent. Funding is trickling to a halt, and there doesn't seem to be any plan to replace or rehab the parts of the machine that are broken. In short, we're in free fall. To make matters even more complex, the foods affected most are ingredients like fresh produce and meats, leaving us scrambling to figure out what's safe and what isn' if you thought a salad was your best bet, you might want to think again. Adding to the running list of fruits and vegetables to use with caution this summer is none other than the season's juiciest and most versatile fruit, the tomato. On May 2, Williams Repack LLC. announced a recall of tomatoes produced on their farms due to potential salmonella contamination, and the FDA updated the recall to Class I on May 28. Class I is the highest recall classification, which means that consuming tainted products could result in serious adverse health consequences or even death. The affected tomatoes were sold and distributed to Georgia, North Carolina, and South Carolina, and there currently isn't a clear picture of what specific stores received them, so it's best to avoid them for now to be safe. You can identify the contaminated product by the brand name H&C Farms or Williams Farms Repack on the label. The tomatoes were distributed between April 23 and April 28 and have UPC number 0 33383 65504 8 and Lot Codes R4467 and R4470. It's also worth noting that wholesalers may have received affected products, potentially widening the scope of the issue. Thankfully, all identified tomatoes have been removed from stores and are no longer available for purchase, but you may still want to tread lightly if you live in any of the impacted states. It looks like Tomato Girl summer is off to a pretty rocky start. We might just stick to growing our own FDA Just Updated a Recall on This Popular Summer Produce To Its Highest Classification—Here's What to Know first appeared on Parade on Jun 3, 2025 This story was originally reported by Parade on Jun 3, 2025, where it first appeared.
Yahoo
18 minutes ago
- Yahoo
FDA To Review Safety Of Abortion Pill After Junk Science Report Paved The Way
Republican Sen. Josh Hawley's quest to legitimize a junk science report undermining the safety of a widely used abortion pill was fully realized this week. Food and Drug Administration Commissioner Martin Makary confirmed in a Monday letter to the Missouri senator that the agency will conduct a safety review of the abortion pill mifepristone. Makary's letter is in response to an April request from Hawley for the department to review mifepristone following a new report published by the Ethics and Public Policy Center, an anti-abortion conservative think tank and advisory board member of Project 2025. 'As with all drugs, FDA continues to closely monitor the postmarketing safety data on mifepristone for the medical termination of early pregnancy,' Makary wrote in his letter. 'As the Commissioner of Food and Drugs, I am committed to conducting a review of mifepristone and working with the professional career scientists at the Agency who review this data.' The FDA and the Department of Health and Human Services did not immediately respond to HuffPost's request for comment. Although Makary does not mention the EPPC report, Hawley's entire argument for reviewing mifepristone relies on the junk science paper. The EPPC report claims it's the 'largest-known study of the abortion pill' and that nearly 11% of women 'experience sepsis, infection, hemorrhaging, or another serious adverse event within 45 days following a mifepristone abortion.' But data scientists voiced serious concerns about the validity of the report, pointing out that it's not peer-reviewed and the report's recommendations do not line up with the data they analyzed. 'It is highly concerning that the FDA is committed to a new review of mifepristone, given the massive amount of evidence on its safety and efficacy,' said Dr. Angel Foster, co-founder of the Massachusetts Medication Abortion Access Project, a shield law practice that provides telehealth abortion care to people in all 50 states. 'This is purely politically motivated and not rooted in science,' Foster said. 'Rolling back access to mifepristone would be a disaster, especially for the patients that The MAP serves every day – patients living in states where abortion is banned, who can't afford to pay for a procedure, and for whom neither traveling to another state nor remaining pregnant are options.' Republicans have been laying the groundwork to undermine the safety of mifepristone for months. It makes sense that anti-abortion groups have set their sights on the pill: telehealth abortion care now accounts for 20% of all abortion care since the Supreme Court repealed Roe v. Wade. Democrats have repeatedlygrilled Makary and HHS Secretary Robert F. Kennedy Jr. about their plans for mifepristone. The FDA commissioner's promise to review the abortion pill stands in stark contrast to his past statements that he has 'no plans' to restrict mifepristone. But Makary has repeatedly left the door open, hinting that if there was reason to believe mifepristone was unsafe his agency would review it. Makary has not once stated mifepristone's proven safety record since the FDA approved it in 2000. The medication has been used safely by over 6 million people in the U.S., according to the agency. Major medical groups have repeatedly said mifepristone is safe, pointing to more than 100 studies that have corroborated its safety and effectiveness. During a recent Senate appropriations hearing, Sen. Patty Murray (D-Wash.) asked Makary about the EPPC report and whether he would use it in his approach to mifepristone. Makary said he would want to see the underlying data of the study, but took issue with Murray's characterization of the EPPC paper as a 'sham study.' 'I have not seen that study, senator, and you have not seen that study,' Makary responded. 'So how can you call it a sham, bogus study? Neither of us have seen the study, the underlying data, or the methodology.' The FDA did not respond to HuffPost when asked if Makary's decision to review mifepristone stemmed from the EPPC report or if he's seen its underlying data. 'Even apart from all the red flags with the data and supposed analysis, the fact where they land in the recommendations — that has nothing to do with the research itself — indicates this was driven more by ideology than by scientific rigor,' Rachel Jones, a principal research scientist at the Guttmacher Institute, said of the EPPC report in April. Jones told HuffPost that she would not call the paper a 'study' since it's impossible for other researchers to fully assess the methodology and integrity of its results without access to the underlying data. 'We've known this moment was coming, and we've been sounding the alarm on Martin Makary since his nomination,' Reproductive Freedom for All President and CEO Mini Timmaraju said in a Tuesday statement. 'After months of signals and dog whistles, it's now in black and white on official FDA letterhead,' she continued. 'This review is not grounded in new data or real safety concerns – it's driven by Project 2025-aligned groups and right-wing politicians who want to ban abortion nationwide. We are now one step closer to the Trump administration's ultimate goal of a national abortion ban.' GOP Lays Groundwork To Restrict Abortion Pill With New Junk Science Report Trump DOJ Just Sided With Biden On Abortion Pill Case – But It's Not What You Think Josh Hawley Introduces Law To Ban Mailing Of Abortion Pills, Citing Junk Science Report
Yahoo
18 minutes ago
- Yahoo
Social Rundown: Decades old submarine, Study helps pets live longer, Unhinged job landings
WICHITA FALLS (KFDX/KJTL) — Welcome back to the Social Rundown, where you can learn about the online trends happening globally and in Texoma, too! Want to get the latest tea or news on what's trending on social media? Tune in daily! A 108-year-old submarine that crashed and sank during an exercise training in 1917 was deemed lost, but was now found after deep-sea training off the coast of San Diego. Through a research study and clinical trial, your pet may now have the opportunity to live a longer life. The Stay Study is in the final test before Company Loyal submits to the FDA for approval. People on the job hunt are likely tweaking their resumes, cover letters, and networking strategies to make themselves more presentable, but others have gone to extreme lengths to land the job. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
